Navigation Links
ESHRE launches international study of polar body screening
Date:6/28/2009

Amsterdam, The Netherlands: The efficacy of preimplantation genetic screening (PGS) has been one of the most hotly disputed subjects in assisted reproduction over the past few years. None of the trials carried out so far has shown conclusively whether it works or not. Now the European Society of Human Reproduction and Embryology (ESHRE) Task Force on PGS has decided to try to find out if a novel method of doing PGS using polar body biopsy and chromosome array analysis offers a possible solution.

Professor Joep Geraedts, ESHRE chairman, told the 25th annual conference of the society today (Sunday June 28) that the Task Force would carry out a pilot study of PGS in one of each pair of 23 chromosomes in polar bodies, tiny cells that are a by-product of egg development, in collaboration with BlueGnome, a DNA technology company based in Cambridge, UK. Once a pilot study has shown that the technique is feasible, the researchers intend to carry out an international randomised trial.

The first phase will begin in September 2009 in two centres: the University of Bonn, Germany (Dr. Markus Montag and Professor Hans van der Ven), and SISMER, Bologna, Italy (Dr. Luca Gianaroli and Dr. Cristina Magli). "Because this is a new technology," said Dr. Gianaroli, "we need to carry out a pilot study in order to be sure that the analysis can be completed within a time period that allows for fresh transfer, as well as to ensure the reliable identification of the chromosomal status of an oocyte in at least 90% of polar body biopsy attempts."

The two centres chosen for the pilot study have considerable experience in the field of polar body biopsy because legislation in their countries restricts the possibility of undertaking embryo biopsy at a later stage of development. The data from the study will be independently analysed by Dr. Sjoerd Repping, from the Academic Medical Centre in Amsterdam, who carried out a randomised trial of PGS on three-
'/>"/>

Contact: Mary Rice
mary@mrcommunication.org
European Society for Human Reproduction and Embryology
Source:Eurekalert

0

GOOD

Page: 1 2

Related biology news :

1. Nutricia launches Nutra Neocate, weaning product designed for cows’ milk protein allergy
2. Swiss Initiative in Systems Biology launches new projects
3. Springer launches StemCellGateway.net
4. Springer launches SpringerExemplar.com
5. UC Davis launches One Health care for wild mountain gorillas and human neighbors
6. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
7. Futronic Launches FS90 USB2.0 Mini Fingerprint Scanner
8. Iowa State chemist synthesizes carbohydrates, launches startup company
9. LabRoots Launches Social Networking Site for Scientists & Engineers
10. Stanford launches $100 million initiative to tackle energy issues
11. From sheet metal elements to host cells: DFG launches 10 new collaborative research centers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...ISON This week, scientists are revealing the gene... cereal crops. Corn, or maize, has one of the most...ersity of Wisconsin-Madison genomicist David Schwa...rticle in the journal Science . , "The maize ge... dead-ends that have troubled would-be sequencers ...
(Date:11/19/2009)... , WALL, N.J., Nov. 19 /PRNewswire-FirstCal...ard: BKYI), a leader in wireless public safety and...announced that the Special Shareholder Meeting hel...en because a quorum was not present. ,, (Logo: ...EYLOGO) ,, While an impressive 99.3% of the 35 ...
(Date:11/19/2009)...ACA, N.Y. - A new study of maize has identified th...le portions of the genome. New techniques may allo...iation to identify desirable traits and create new..., Publishing in the Nov. 19 issue of Science , t...at Cornell, have identified the first map of haplo...
Breaking Biology News(10 mins):Sweet corn story begins in UW-Madison lab 2Sweet corn story begins in UW-Madison lab 3BIO-key(R) Provides Update to Special Shareholder Meeting 2BIO-key(R) Provides Update to Special Shareholder Meeting 3New map of variation in maize genetics holds promise for developing new varieties 2Dendreon Announces Webcast Presentations at Upcoming Investor Conferences 12482 1Bart Peterson to Join Lilly Leadership Team 48032 1Bart Peterson to Join Lilly Leadership Team 48032 2Bart Peterson to Join Lilly Leadership Team 48032 3Akaza Research to Present and Exhibit at Upcoming DIA Annual Meeting 12481 1Akaza Research to Present and Exhibit at Upcoming DIA Annual Meeting 12481 2
...p revolutionary drug delivery methods that are mor...ions of patients. , Chemists at The University of... drugs in plastics, using methods that do not dama...ical drugs which are at the cutting edge of modern...ting drugs can use high temperatures and harsh sol...
...ional (CI) today announced a partnership with Toyo...than 4,000 acres of the Philippines Peablanca Prot...e Northeastern part of one of the nations main isl...l communities will receive additional benefits fro...ment. , The site was chosen to launch the partner...
...he Neanderthals died out because of competition wi...tic conditions. Although scientists have gained in...icult to pinpoint the climatic character at the ti...y an international team of researchers, published ...eveloped a breakthrough approach to address this i...
Other Biology News:Using green chemistry to deliver cutting-edge drugs 2Using green chemistry to deliver cutting-edge drugs 3Using green chemistry to deliver cutting-edge drugs 4Conservation International and Toyota partner to protect Philippines' rain forests 2Conservation International and Toyota partner to protect Philippines' rain forests 3Climate -- no smoking gun for Neanderthals 2
(Date:11/19/2009)..., ,, BETHESDA, Md., Nov. 19 /PRNewswire-Fir...an innovator in biotechnology for diabetes therapy...lting services to food, supplement, biotechnology ...losed the previously reported $6.3 million registe... 2,760,870 shares of its common stock and warrants...
(Date:11/19/2009)...MONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeuti...tient in a randomized Phase 2B study of AEG35156, ...lopment for multiple oncology indications. ,, T... 2 Study of the X-Linked Inhibitor of Apoptosis (X...High-dose Cytarabine and Idarubicin in AML Followi...
(Date:11/18/2009)...AVIS, Calif., Nov. 18 Marrone Bio ...lopment and commercialization of effective and env... announced that it has been named an IC20 company ...t and largest national angel investing group. ,... leading to rewarding results for all stakeholders...
(Date:11/18/2009)... RICHMOND, Calif., Nov. 18 /PRNewswire-FirstCall/ ...unced today that data from the University of Penns...y of Sangamo,s zinc finger nuclease (ZFN) based pr...nd prematurely disclosed on the internet. ,, Da...rsity of Pennsylvania School of Medicine from a si...
Breaking Biology Technology:Spherix Announces the Closing of $6.3 Million Registered Direct Offering 2Spherix Announces the Closing of $6.3 Million Registered Direct Offering 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2Marrone Bio Innovations Named an IC20 Company 2Sangamo BioSciences Provides Update on Phase 1 Safety Trial of SB-728-T for HIV/AIDS 2
... Even with layoff announcements...employment continued to increase in September, gai...th it seemed like no one was searching for those n...ocus) October 31, 2008 -- Strong growth continues ...0 jobs created each month. Even with layoff announ...
...GO, Oct. 30 Accumetrics, Inc. has appointed,Timot...ecutive Officer. Mr.,Still has been serving in the... for the company since earlier this year., "Tim h...and startup,experience for our Board," says Tony A... Executive Chairman of the Board at Accumetrics. "...
...GE, Mass., Oct. 30 Idenix,Pharmaceuticals, Inc. (...ed,in the discovery and development of drugs for t...iseases, today reported unaudited financial result...ember 30, 2008. At,September 30, 2008, Idenix,s ca...aled approximately $60.1 million., 2008 Year-to-D...
Other Biology Technology:The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 2The MedZilla Report: September 2008 Employment Outlook for Biotech/Pharma/Health 3Timothy I. Still Appointed CEO at Accumetrics 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 2Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 3Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 4Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 5Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 6Idenix Pharmaceuticals Reports Third Quarter and Nine Month Financial Results 7
...nterferons are cytopathic effect inhibition assays...types include; tissue culture supernatents; serum ...se assays, one unit is defined as the quantity of ...ytopathic effect of viral infection by 50%. All ...
Guanylyltransferase (5 U/l) from Ambion
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
...Nebulizers are available in two product models - t...se two models is that the 6000AT+ includes a membr...er aerosol for improved detection limits and reduc...tion limits for a range of elements by 10-40 times...
Biology Products: